Siamycin 1

Drug Profile

Siamycin 1

Alternative Names: BMY 29304; Siamycin I

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antibacterials; Antivirals
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 02 Sep 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
  • 22 May 1995 New profile
  • 22 May 1995 Preclinical development for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top